New Marie Skłodowska-Curie Doctoral Network advances AI solutions for Parkinson’s disease

Neurological disorders are now the leading cause of disability worldwide. Parkinson’s disease is the second most common neurodegenerative disorder, and case numbers are growing quickly.

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

Japanese drugmaker Kyowa Kirin is acquiring most of the commercial rights for Kura Oncology’s targeted leukemia treatment, paying $330 million upfront and almost $1.2 billion

November 22, 2024

New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition

MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by

April 28, 2024

Lonza nominates Juan Andres and Eric Drapé as independent Board Members

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.